E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer |
|
E.1.1.1 | Medical condition in easily understood language |
lung cancer, ovarian cancer, or breast cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029519 |
E.1.2 | Term | Non-small cell lung cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029522 |
E.1.2 | Term | Non-small cell lung cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10059515 |
E.1.2 | Term | Non-small cell lung cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10057529 |
E.1.2 | Term | Ovarian cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10070907 |
E.1.2 | Term | Ovarian cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10070908 |
E.1.2 | Term | Ovarian cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006201 |
E.1.2 | Term | Breast cancer stage III |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006202 |
E.1.2 | Term | Breast cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10055113 |
E.1.2 | Term | Breast cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
to evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy |
|
E.2.2 | Secondary objectives of the trial |
-to compare the treatment effect of romiplostim with that of placebo on the depth of platelet nadir -to compare the treatment effect of romiplostim with that of placebo on the time to first platelet response -to compare the treatment effect of romiplostim with that of placebo on the incidence of > grade 2 bleeding events -to compare the treatment effect of romiplostim with that of placebo on overall survival -to compare the treatment effect of romiplostim with that of placebo on the incidence of platelet transfusions -to compare the treatment effect of romiplostim with that of placebo on the proportion of patients achieving platelet response -overall safety of romiplostim |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject has provided informed consent prior to initiation of any study-specific activities/procedures or subject’s legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent. 2. Males or females > 18 years of age at signing of the informed consent. 3. Documented active stage I, II, III or IV locally advanced or metastatic of the following tumor types: NSCLC, breast cancer, or ovarian cancer (includes fallopian tube epithelial carcinomas and peritoneal epithelial carcinoma of unknown primary), or any stage recurrent disease. •patients with documented locally advanced (stage III) NSCLC should not be amenable to definitive treatment with chemoradiation and/or surgery. 4. Subjects must be receiving cancer treatment with 21- or 28-day cycles, using one of the following carboplatinum-based combination chemotherapy regimens: carboplatin/gemcitabine based, carboplatin/pemetrexed based, carboplatin/liposomal doxorubicin based or carboplatin/taxane based (which includes either paclitaxel, nab-paclitaxel, or docetaxel). Use of combination regimens with one of the above carboplatinum-based regimens is permitted with (1) anti-angiogenic agents (such as bevacizumab); (2) targeted therapy (such as anti-epidermal growth factor agents or anti- human epidermal growth factor receptor 2) or (3) immune checkpoint inhibitors. Cycle duration is based on intervals between day 1 of chemotherapy cycles (overlapping with carboplatin intervals) every 21 or 28 days.
OR
Subjects must have CIT from a non-protocol chemotherapy regimen, planning to start treatment with one of the above protocol chemotherapy regimens which has been delayed ≥ 1 week due to CIT. 5. Subjects must have a local platelet count < 85 x 109/L on study day 1. 6. Subjects must be at least 21 or 28 days removed from the start of the chemotherapy cycle immediately prior to study day 1 if receiving a 21-day or 28-day cycle chemotherapy regimen, respectively. 7. Subjects must have at least 3 remaining planned cycles of chemotherapy at study enrollment. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
|
|
E.4 | Principal exclusion criteria |
1.Acute lymphoblastic leukemia.2.Acute myeloid leukemia.3.Any myeloid malignancy.4.Myelodysplastic syndrome. Baseline bone marrow biopsy is not required to rule out MDS. However,if a bone marrow biopsy and cytogenetics were performed as part of diagnostic or staging workup,these results will be collected to confirm.5.Myeloproliferative disease.6.Multiple myeloma.7.Within 4 months prior to enrollment, any history of active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, screening ECG with corrected QT (QTc) interval of > 470 msec, pericardial disease, or myocardial infarction.8.Major surgery <28 days or minor surgery < 3 days prior to enrollment9.New or uncontrolled venous thromboembolism or thrombotic events within 3 months prior to screening. 10.History of arterial thrombotic events (eg, myocardial ischemia, transient ischemic attack, or stroke) within 6 months prior to screening11.Evidence of active infection within 2 weeks prior to the first dose of study treatment12.Known human immunodeficiency virus infection. 13. Known active of chronic hepatitis C or hepatitis B infection. 14. In addition to the conditions listed in exclusion criteria 201 through 206, secondary malignancy within the past 5 years except: •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. •Adequately treated cervical carcinoma in situ without evidence of disease. •Adequately treated breast ductal carcinoma in situ without evidence of disease •Prostatic intraepithelial neoplasia without evidence of prostate cancer. •Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ. Malignancy treated with curative intent and with no known active disease present for >3 years before enrollment and felt to be at low risk for recurrence by the treating physician.15.Thrombocytopenia due to another etiology other than CIT16. Any combined modality regimen containing radiation therapy or surgery occurring concomitantly with neo-adjuvant chemotherapy or where radiation therapy is planned before the 3 planned on-study cycles of chemotherapy.17.Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and dev factor, eltrombopag, recombinant human TPO, any other TPO receptor agonist, or any investigational platelet producing agent.18.Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigtnl procedures while participating in this study are excluded.19. Anemia (hemoglobin <80 g/L [8 g/dL)]) on the day of initiation of investigtnll product as assessed by local labs. Use of red cell transfusions and erythropoietic stimulating agents is permitted throughout the study as per institutional guidelines.20.Neutropenia (absolute neutrophil count <1 x 109/L) on the day of initiation of investigtnl product as assessed by local labs. 21.Abnormal renal function with creatinine clearance <30 mL/min using the Cockcroft-Gault estimated creatinine clearance as assessed by local lab during screening. If local lab results are not available use central lab results.22. Abnormal liver function as assessed by central lab during screening.23. Females who are preg or breastfeeding or planning to become preg or breastfeed during treatment and for an additional 7 months aftr treatment (and chemotherapy) discontinuation.24.Females of childbearing potential unwilling to use a highly effective method of contraception during treatment and for an additional 7 months after treatment(and chemotherapy) discontinuation. 25. Males unwilling to use contraception* (male condom or sexual abstinence) or their female partner(s) of childbearng potential who are unwilling to use a highly effective method of contraception during treatment (and chemotherapy) and for an additional 7 months after treatment (and chemotherapy) discontinuation. *If the male’s sole partner is of non childbearng potential, he isnt required to use additional forms of contraception during the study.26.Subject has known sensitivity to any of the products to be administered during dosing.27.Subject likely to not be availabl to complete/comply with all protocol-required study visits or procedures.28.History or evidence of any other clinically significant disorder, condition or disease tht would pose a risk to subject safety or interfere with study evaluation, procedures or completion.29. Male subjects with a pregpartner who are unwilling to practice abstinence or use a condom during treatment (and chemotherapy) and for an additional 7 months after treatment (and chemotherapy) discontinuation.30. Male subjects unwilling to abstain from donating sperm during treatment (and chemotherapy) and for an additional 7 months after treatment (and chemotherapy) discontinuation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
no thrombocytopenia-induced modification of any myelosuppressive agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 109/L. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
-The primary analysis will be performed at the primary completion date. The primary completion date is defined as the date when the last subject is assessed or receives an intervention for the final collection of data for the primary endpoint. |
|
E.5.2 | Secondary end point(s) |
- the depth of the platelet count nadir from the start of the first on-study chemotherapy cycle through the end of the treatment period -the time to first platelet response, defined by platelet count 100 x 109/L in the absence of platelet transfusions during the preceding 7 days -the duration-adjusted event rate of grade 2 bleeding events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading scale -overall survival -platelet transfusion(s) during the treatment period -achieving a platelet count 100 x 109/L at any time after study day 1 to week 4 (i.e. 7 days after the planned third dose of investigational product) and in the absence of platelet transfusions during the preceding 7 days -adverse events, including treatment-emergent adverse events, fatal adverse events, serious adverse events,and clinically significant changes in laboratory values -anti-romiplostim antibodies and antibodies to thrombopoietin (TPO) -myelodysplastic syndromes and secondary malignancies |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-The primary analysis will be performed at the primary completion date. The primary completion date is defined as the date when the last subject is assessed or receives an intervention for the final collection of data for the primary endpoint
-When the last subject in the trial completes LTFU at 1 year after the last dose of investigational product, the final database will be locked and for the final analysis. In the final analysis, the secondary endpoints assessment, and all the exploratory endpoints will be evaluated |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 54 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Canada |
Chile |
Colombia |
Mexico |
Peru |
Russian Federation |
Ukraine |
United States |
Austria |
Greece |
Hungary |
Poland |
Portugal |
Bulgaria |
Romania |
Spain |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study (EOS) date is defined as the date when the last subject across all sites is assessed or receives an intervention for evaluation in the study (i.e. last subject last visit), following any additional parts in the study (eg, LTFU), as applicable. Based on the definition above, the EOS date is the date when the last subject in the trial has completed his/her EOS visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 1 |